Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31674529 | 1.00 | RAB9A (0.40) | RAB9AKDM4EMEN1KMT2AUSP2 | |
| SCHEMBL21995567 | 0.74 | PIK3CD (0.48) | RAB9AKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL31674513 | 0.74 | PIK3CD (0.48) | RAB9AKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL21995535 | 0.71 | KDM4E (0.49) | RAB9AKDM4EMEN1KMT2AUSP2 | |
| SCHEMBL1257460 | 0.67 | PIK3CD (0.73) | RAB9AKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2823763 | 0.64 | RAB9A (0.57) | RAB9AKDM4EMEN1KMT2AUSP2 | |
| SCHEMBL9815169 | 0.63 | CES2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL7329821 | 0.63 | CES2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL17817574 | 0.63 | CES2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL10357516 | 0.63 | CES2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3887358-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166076-A | Heterocyclic compounds for the treatment of epilepsy | 大塚制药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020111263-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | RAB9A 2321/4885KDM4E 779/4885MEN1 450/4885 |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, KCNH1 | RAB9A 2152/4885KDM4E 1095/4885MEN1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.